S264: EDIT-301 SHOWS PROMISING PRELIMINARY SAFETY AND EFFICACY RESULTS IN THE PHASE I/II CLINICAL TRIAL (RUBY) OF PATIENTS WITH SEVERE SICKLE CELL DISEASE USING HIGHLY SPECIFIC AND EFFICIENT ASCAS12A ENZYME

• Rabi Hanna,
• Haydar Frangoul,
• Christopher Mckinney,
• Luis Pineiro,
• Markus Mapara,
• Kai-Hsin Chang,
• Michael Jaskolka,
• Keunpyo Kim,
• Maha Rizk,
• Olubunmi Afonja,
• Adebayo Lawal,
• Mark Walters

Affiliations

Rabi Hanna

1 Cleveland Clinic, Department of Pediatric Hematology Oncology and Blood and Marrow Transplantation, Cleveland, United States

Haydar Frangoul

2 Children’s Hospital at TriStar Centennial, Sarah Cannon Center for Blood Cancer, Nashville, United States

Christopher Mckinney

3 Anschutz Medical Campus, Children’s Hospital of Colorado, Aurora, CO, United States

Luis Pineiro

4 Baylor University Medical Center, Blood and Marrow Transplant Program and Marrow Processing Laboratory,, Dallas, TX, United States

Markus Mapara

5 Columbia University Irving Medical Center, Bone Marrow Transplantation and Cell Therapy Program, New York City, NY, United States

Kai-Hsin Chang

6 Editas Medicine, Inc., Cambridge, MA, United States

Michael Jaskolka

6 Editas Medicine, Inc., Cambridge, MA, United States

Keunpyo Kim

6 Editas Medicine, Inc., Cambridge, MA, United States

Maha Rizk

6 Editas Medicine, Inc., Cambridge, MA, United States

Olubunmi Afonja

6 Editas Medicine, Inc., Cambridge, MA, United States

Adebayo Lawal

6 Editas Medicine, Inc., Cambridge, MA, United States

Mark Walters

7 University of California, San Francisco and Benioff Children’s Hospital, School of Medicine, Oakland, CA, United States